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Summary
Cancer is an aging-associated disease, but the underlying molecular links between
these processes are still largely unknown. Gene promoters that become hyperme-
thylated in aging and cancer share a common chromatin signature in ES cells. In
addition, there is also global DNA hypomethylation in both processes. However, the
similarity of the regions where this loss of DNA methylation occurs is currently not
well characterized, and it is unknown if such regions also share a common chro-
matin signature in aging and cancer. To address this issue, we analyzed TCGA DNA
methylation data from a total of 2,311 samples, including control and cancer cases
from patients with breast, kidney, thyroid, skin, brain, and lung tumors and healthy
blood, and integrated the results with histone, chromatin state, and transcription
factor binding site data from the NIH Roadmap Epigenomics and ENCODE projects.
We identified 98,857 CpG sites differentially methylated in aging and 286,746 in
cancer. Hyper- and hypomethylated changes in both processes each had a similar
genomic distribution across tissues and displayed tissue-independent alterations.
The identified hypermethylated regions in aging and cancer shared a similar bivalent
chromatin signature. In contrast, hypomethylated DNA sequences occurred in very
different chromatin contexts. DNA hypomethylated sequences were enriched at
genomic regions marked with the activating histone posttranslational modification
H3K4me1 in aging, while in cancer, loss of DNA methylation was primarily associ-
ated with the repressive H3K9me3 mark. Our results suggest that the role of DNA
methylation as a molecular link between aging and cancer is more complex than
previously thought.
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1 | INTRODUCTION
Age is among the most important risk factors for cancer (de
Magalh~aes, 2013; DePinho, 2000). However, the underlying molecu-
lar mechanisms governing this relationship are still poorly under-
stood. Recent research has established polycomb-target gene
promoter hypermethylation as a common epigenetic characteristic of
cancer (Schlesinger et al., 2007; Widschwendter et al., 2007). In this
scenario, prior to alteration these promoters display an embryonic
stem cell “bivalent chromatin pattern” consisting of the repressive
histone mark H3K27me3 and the active mark H3K4me3 (Ohm et al.,
2007). Genes affected by this process are associated with develop-
mental regulation (Easwaran et al., 2012), implying a possible stem
cell origin of cancer whereby aberrant hypermethylation could pro-
mote a continuously self-renewing embryonic-like state in cancer
cells (Teschendorff et al., 2010). Interestingly, promoter hypermethy-
lation of polycomb-target genes was later described in aging blood
(Rakyan et al., 2010; Teschendorff et al., 2010) and other tissue
types such as mesenchymal stem cells (Fernandez et al., 2015), ovary
(Teschendorff et al., 2010), brain, kidney, and skeletal muscle (Day
et al., 2013), findings which were also confirmed using whole-gen-
ome bisulfite sequencing (Heyn et al., 2012).
In addition to aberrant locus-specific DNA hypermethylation,
tumoral cells are also globally hypomethylated as compared to their
healthy counterparts. While this molecular alteration preferentially
occurs at gene bodies, intergenic DNA regions, and repeated DNA
elements (Ehrlich, 2009) and is proposed to be associated with chro-
mosomal instability, reactivation of transposable elements, and loss
of genomic imprinting, its precise functional role in cancer develop-
ment is still poorly understood (Rodrıguez-Paredes & Esteller, 2011).
Intriguingly, global loss of genomic DNA methylation has also been
reported during the aging and senescence process (Cruickshanks
et al., 2013; Fraga & Esteller, 2007). Whole-genome bisulfite
sequencing and methylation arrays have confirmed the global loss of
DNA methylation in different human tissues including blood (Heyn
et al., 2012), mesenchymal stem cells, and brain (Fernandez et al.,
2015). On the other hand, other important tissues such as skeletal
muscle do not seem to become hypomethylated with aging (Zyko-
vich et al., 2014).
Despite the interesting parallelism in aging and cancer recently
reported with respect to hypermethylated DNA regions, the rela-
tionship between hypomethylated DNA sequences in these two
processes has not been sufficiently studied. Moreover, recent analy-
ses mainly performed in mouse tissue have failed to confirm global
hypomethylation during the aging process (Cole et al., 2017; Hahn
et al., 2017; Masser et al., 2017) and, to date, no study has
provided a back-to-back and systematic comparison of the epige-
netic changes that occur in aging and cancer. To address this issue,
here we have analyzed DNA methylation changes and their associ-
ated chromatin patterns in a total of more than 2,300 healthy and
tumoral samples obtained from differentially aged individuals, using
HumanMethylation450 BeadChip data generated by The Cancer
Genome Atlas (TCGA) consortium and other datasets (Bormann
et al., 2016; Guintivano, Aryee & Kaminsky, 2013; Hannum et al.,
2013). Our results confirmed the relationship between DNA hyper-
methylation in aging and cancer, but they also revealed important
differences in DNA hypomethylation changes in the two processes
that might be important to understand the possible role of DNA
methylation as a molecular link between decline related to aging
and tumor development.
2 | RESULTS
2.1 | DNA methylation profiling in aging and cancer
To identify DNA methylation changes in aging and cancer, we col-
lected DNA methylation data obtained with the HumanMethyla-
tion450 BeadChip (Illumina) (see Section 4) and compared the DNA
methylation status of a total of 361,698 CpG sites across 1,762 sam-
ples corresponding to healthy and tumoral tissues obtained from dif-
ferentially aged patients with breast, kidney, thyroid, skin, and brain
tumors (see Tables 1 and S1 for extended information). Using an
empirical Bayes moderated t test (see Section 4), we identified a
high number of autosomal differentially methylated CpGs (dmCpGs;
FDR < 0.05) between normal and tumoral samples, while a lower
and more variable number of aging-related dmCpGs between young
and old samples was found (Table 1; Figure 1a and Table S2 for
additional information). Hierarchical clustering of samples using the
dmCpGs enabled us to distinguish between tumoral and control sam-
ples with more efficiency than young and old samples (Figure 1b
and Figure S1). On the whole, whereas cancer-related DNA methyla-
tion changes had no dominance of either hyper- or hypomethylation,
aging-related changes tended toward DNA hypermethylation, and
showed a much more variable and tissue type-dependent magnitude
of change. Globally, methylation changes were found to be more
pronounced in cancer than in aging (Figure 1c and Table S3, Wil-
coxon tests; all p < .05), while comparison of hyper- vs. hypomethy-
lation changes was variable and disease and tissue type dependent.
Intriguingly, most tumors obtained from differentially aged patients
did not show significant age-associated DNA methylation changes,
with the exception of thyroid cancer (Table 1, Figure 1a, bottom
panel and Table S2). Furthermore, analyses employing Horvath’s
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predictor revealed that thyroid cancer had the highest correlation of
real-vs.-predicted age across all the cancer types in our dataset
(Figure 1d).
2.2 | Genomic distribution of dmCpGs in aging and
cancer
The study of the genomic distribution of the dmCpGs revealed that
hypomethylated CpG sites followed a similar disease and tissue-inde-
pendent trend, being preferentially found at low-density CpG DNA
regions interrogated by the array in both cancer and aging (average
median difference compared to array 49%, Wilcoxon tests; all
p < .001) (Figure 2a; see also Table S4). Consequently, with respect
to the array, these hypomethylated CpG sites were enriched at open
sea locations and intronic and intergenic regions (Fisher’s tests; all
p < .001, all odds ratios (ORs) >2.25, >1.34, and >1.21, respectively,
except nonsignificant thyroid aging) while impoverished at CpG
islands and gene promoters (Fisher’s tests; all p < .001, all ORs<0.43
and <0.64, respectively) (Figure 2b,c; Figure S2 and Table S5). Den-
sity of hypermethylated CpG sites in cancer was variable but compa-
rable to background array density (average median difference
<12%, Wilcoxon tests; all p < .001), whereas a noticeably high
CpG density was found for breast, kidney, and thyroid in the aging
context (average median difference 44%, Wilcoxon tests; all
p < .001). Consequently, these dmCpGs were enriched at CpG
islands and gene promoters (Fisher’s tests; all p < .001, all ORs>1.89
and >1.08, respectively).
Comparative enrichment analysis confirmed that DNA
hypomethylation in aging and cancer mainly occurred at low CpG
density DNA regions located at introns, open sea, and intergenic
DNA regions, while hypermethylation distribution was more irregular
and more similar to array distribution. Nonetheless, a common and
strong tendency was found when comparing hyper- to hypomethyla-
tion changes in both aging and cancer, whereby hypermethylation
changes always occurred in regions with a higher CpG density than
did hypomethylation changes (average median difference 51%,
Wilcoxon tests; all p < .001) (Figure 2a and Table S4), resulting in
strong differences in local enrichments at CpG islands and open sea
locations, as well as gene promoters and intergenic regions, in most
cases (Figure 2b,c; Figure S3 and Table S5), with this effect being
even more pronounced for the aging dmCpGs.
2.3 | Tissue type-independent DNA methylation
changes in aging and cancer
To determine the effect of tissue type on the DNA methylation
changes during aging and cancer, we compared the previously identi-
fied dmCpG sites for each of the tissues. In cancer, ~50% of hyper-
and hypomethylated CpGs were common to at least two different
tumor types (Figure 3a), with 1,962 (1.1%) hyper- and 2,708 (1.5%)
hypomethylated CpG sites being common to all five tumor types
analyzed (Figure 3b and Table S6). In contrast, the overlap between
dmCpGs in aging across different tissues was considerably reduced.
Indeed, only 18% of the hyper- and 8% of the hypomethylated CpG
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sites were common to at least two tissue types and only 89 (0.15%)
hyper- and 1 (0.002%) hypomethylated CpG sites were common to
all five tissue types analyzed (Figure 3a,b and Table S6). However,
statistical analyses of the pairwise overlaps between the different
sets of probes showed overall enrichment in every case, especially
for aging (Figure 3d, Fisher’s tests; all p < .001, Table S7). This over-
enrichment was also revealed through a simulation of a random
sampling of probes from the array (Figure S4a). Taken together,
these results suggest that both cancer and aging manifest tissue-
independent changes in DNA methylation.
We also identified a subset of dmCpG sites in aging and can-
cer that could potentially be either hyper- or hypomethylated
depending on the tissue type involved (Figure 3c) and showed
substantial under-enrichment (Fisher’s test p < .001 for both,
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diagrams depicting the number of differentially hyper- and hypomethylated CpGs in aging and cancer shared by the different tissues. (c) Venn
diagrams showing the number and overlap of total nonredundant hyper- and hypomethylated dmCpGs detected in cancer and aging. (d)
Heatmaps showing pairwise comparisons between sets of probes: in green, Jaccard Indices; in red, odd ratios (all enrichment Fisher’s tests
p < .001)
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ORs = 0.65 and 0.56; expected hypergeometric means,
EHMs = 94,610 and 7,060; and Jaccard indices, JIs = 0.30 and
0.05, respectively). Interestingly, when examining dmCpGs shared
by two or more tissues (Figure S4b), this under-enrichment
became more pronounced such that CpGs that were thus affected
in more than one tissue were less likely to behave differently in
other tissues.
2.4 | Similar chromatin signatures of DNA
hypermethylation in aging and cancer
To identify possible chromatin marks associated with hypermethy-
lated CpG sites in aging and cancer, we compared the hypermethy-
lated CpG sites identified in this study with previously published
ENCODE and NIH Roadmap Epigenomics ChIP-seq data on the his-
tone modifications H3K4me1, H3K4me3, H3K27ac, H3K36me3,
H3K27me3 and H3K9me3 across 98 different cell and tissue types
(see Section 4). The results confirmed an enrichment of hypermethy-
lated CpG sites in repressive histone modifications H3K27me3 and
H3K9me3 and active histone modifications H3K4me1 and
H3K4me3 in both in aging and cancer (Figure 4a, upper panel;
Table S8), with the H3K27me3 mark being the most consistent
enrichment across all of the analyses. Notably, these similarities
became more pronounced when examining dmCpGs shared by all
five tissue types in cancer, or three of the tissue types in aging (low
numbers of common probes, due to tissue-specificity of aging
dmCpGs, hindered analysis of dmCpGs shared by more tissues).
Interestingly, the embryonic stem cell signature was comparable to
other tissue signatures, although, when present, the H3K4me3 mark
was more evident in the aging context. Collectively, these results
suggest that chromatin signatures of DNA hypermethylation are sim-
ilar in aging and cancer.
2.5 | Distinct chromatin signatures of DNA
hypomethylation in aging and cancer
To determine whether the chromatin signatures of DNA hypomethy-
lation were also similar in aging and cancer, we compared the
hypomethylated CpG sites identified in our study with data from the
same histone modifications as described in the earlier analyses. Inter-
estingly, the results showed that hypomethylated CpG sites in can-
cer were enriched in the repressive H3K9me3 histone modification,
while in aging, hypomethylated CpGs were more enriched in the
activating histone mark H3K4me1 (Figure 4a, lower panel; Table S8).
There were though exceptions to this general trend: hypomethylated
CpG sites in thyroid tumors were also enriched at H3K4me1, and
hypomethylated DNA sequences in aged skin were mainly co-asso-
ciated with H3K9me3-marked DNA regions. Nevertheless, the ratio
H3K4me1/H3K9me3 was always higher in aging than in cancer (Fig-
ure 4b). Moreover, when analyzing the dmCpGs shared by all five
tissues in cancer or at least three tissues in aging, these distinct
chromatin signatures became much more evident. In sum, these
results indicate that, in contrast to DNA hypermethylation,
chromatin signatures of DNA hypomethylation in aging and cancer
differ considerably.
After deriving the chromatin signatures, we performed validation
analyses on two additional datasets: the first related to tissue from
TCGA control and lung adenocarcinoma and the second to whole
blood from the classical Hannum et al. (2013) dataset (Figure S5; see
Table S9 for additional information). Interestingly, we were unable to
find aging-related methylation changes in normal lung tissue using
our pipeline. The magnitude and distribution of the hyper- and
hypomethylation changes in lung cancer and whole blood aging fol-
lowed the same trend as observed for the other datasets (Figure S5a,
see Table S2 for a list of dmCpGs). The histone enrichment analyses
revealed the same hypermethylation signature previously found for
cancer and aging, and very clear and different hypomethylation sig-
natures of H3K9me3 for lung cancer and H3K4me1/3 for whole
blood aging (Figure S5b and Table S8).
Finally, we compared the overlap between either hypermethy-
lated or hypomethylated CpGs across tumors and their correspond-
ing age-related tissues (Figure 4c). This approach revealed that the
overlap between hypermethylated CpGs (24,442 CpGs) was higher
than expected by chance (Fisher’s test p < .001, OR = 2.61;
EHM = 14,689; JI = 0.20) (Figure 4c, upper panel). However, despite
the overlap between hypomethylated CpGs (14,521) also being
slightly higher than expected (Fisher’s test p < .001, OR = 1.60;
EHM = 11,021; JI = 0.12) (Figure 4c, lower panel), the overall trend
observed in this case was weaker than for the hypermethylated
CpGs. Furthermore, most of the hypomethylated probes shared by
cancer and aging belonged to skin dmCpGs, providing evidence for
its similar cancer and aging hypomethylation signatures. Removing
skin tissue from the analysis (Figure S6) caused the observed over-
enrichment to disappear in the case of DNA hypomethylated probes,
although it remained in the hypermethylation scenario (Fisher’s tests,
both p < .001, ORs = 0.8 and 3.0; EHMs = 5,357 and 7,568;
JIs = 0.04 and 0.12, respectively), reinforcing the observed overlap-
ping differences between hyper- and hypomethylated probes.
2.6 | Functional characterization of differentially
methylated sites in aging and cancer
To determine the possible functional consequences and genomic
coincidence of the different histone marks of DNA hyper- and
hypomethylation in aging and cancer, we performed an enrichment
analysis of NIH Roadmap and ENCODE Hidden Markov Model
(HMM) defined “chromatin states” across the same 98 human cell
and tissue types used in the previous analyses (see Section 4). In
total, 18 states were used for the segmentation of the genome,
which were then grouped to highlight predicted functional elements.
As suggested by the earlier chromatin signature analyses, hyper-
methylated CpGs in both aging and cancer were enriched in states
associated with bivalent chromatin domains (i.e., those formed by
the combination of repressive histone mark H3K27me3 and activat-
ing histone marks H3K4me1/3), polycomb repressive domains, and
repeat/ZNF genes. These patterns became more evident when
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examining the dmCpGs shared by all five cancer tissues or at least
three aging tissues (Figure 5a; see Figure S7 for tissue-specific signa-
tures and Table S10 for full data in all 98 cell and tissue types).
Hypomethylated CpG sites in cancer were enriched in chromatin
states associated with heterochromatin and repeat/ZNF gene
domains and, to a lesser extent, polycomb repressive domains. In
contrast, DNA hypomethylation in aging was primarily associated
with chromatin states related to DNA enhancers. Again, these marks
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F IGURE 4 Distinct chromatin signatures of hyper- and hypomethylation in aging and cancer. (a) Heatmaps depicting significant (p < .05)
over-enrichment of hyper- and hypomethylated dmCpG sites with different histone marks in aging and cancer, in a selection of 16 cell and
tissue types (see Table S8 for 98 full cell and tissue types). Color code indicates the significant enrichment based on log2 odds ratio (OR).
Common signatures are calculated from hyper- and hypomethylated dmCpGs shared between five tissues for cancer (1,962 and 2,708 probes,
respectively) or three tissues for aging (904 and 106 probes, respectively) (see Table S6 for CpG lists). (b) Barplots indicating the ratio of OR
for the H3K4me1/H3K9me3 marks associated with hypomethylated dmCpGs in aging and cancer. The ratio is calculated by taking the mean
of OR of those tracks with significant over-enrichment for each histone mark and dividing the obtained numbers. (c) Venn diagrams showing
the number and overlap of total nonredundant hyper- and hypomethylated dmCpGs detected in cancer and aging. dmCpGs that were only
hypermethylated or only hypomethylated between all tissues were chosen for the comparison
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were more pronounced in aging dmCpGs shared by at least three
tissues. As occurred with chromatin signatures, hypomethylation
chromatin state differences were weaker in skin and thyroid, albeit
that the ratio of change of chromatin states always followed the
same behavior (data not shown). Collectively, these results support
the notion that DNA hypomethylation might have a different func-
tional role in aging as compared to cancer.
To increase our understanding of the functional context of the
chromatin signatures characterized, we compared the dmCpG sites
identified in this study with publicly available ENCODE ChIP-seq
data on transcription factor binding sites in 689 datasets corre-
sponding to 188 transcription factors across 91 different cell types
(see Section 4) (Figure 5b; see Figure S8 and Table S11 for full tis-
sue-specific results). As expected, hypermethylated CpGs in aging
and cancer were associated in all tissues with the presence of EZH2
and SUZ12, components of the polycomb complex which directly
deposits the H3K27me3 mark. Interestingly, aging hypermethylation
dmCpGs were specifically associated with other types of transcrip-
tion factors in various tissues, such as REST, HDAC2, RAD21, and
SETDB1. Transcription factor enrichment at hypomethylated dmCpG
sites was more heterogeneous than, but different from that of
hypermethylated sites. Enrichment of similar factors was found for
cancer and aging, for example, EP300, FOS, and JUN, among others.
As observed before, specific aging enrichment was found, such as
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F IGURE 5 Differential chromatin state signatures of hyper- and hypomethylation in aging and cancer. (a) Heatmaps displaying significant
(p < .05) over-enrichment of hyper- and hypomethylated dmCpG sites with different chromatin states in aging and cancer, in a selection of 16
cell and tissue types (see Figure S7 for tissue-specific signatures, and Table S10 for 98 full cell and tissue types). Color code indicates the
significant enrichment based on log2 odds ratio (OR). Common signatures are calculated from hyper- and hypomethylated dmCpGs shared
between five tissues for cancer (1,962 and 2,708 probes, respectively) or three tissues for aging (904 and 106 probes, respectively) (see
Table S6 for CpG lists). (b) Panel indicating significant (p < .05) transcription factor enrichment at hyper- and hypomethylated dmCpG sites in
aging and cancer that occurred in at least four or five tissues (see Figure S8 for tissue-specific results and Table S11 for full data). Only the
most representative transcription factors (those that appeared as significantly over-enriched in at least three tracks or with an OR > 3 in any
track) were selected for data representation
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GATA2/3. In this case, aging hypomethylated dmCpG sites tended
to display a more marked enrichment of most of the cancer
hypomethylation factors and, additionally, revealed the presence of
other family- or function-related proteins, like FOSL1/2, MAFF,
MAFK, and STAT3. When examining enrichment at common dmCpG
sites shared by different tissues in cancer and aging, the initial obser-
vations were further confirmed (Figure S9).
Gene ontology analyses (Figure 6a; Table S12; see Figure S10
for tissue-specific results) revealed that hypermethylated CpGs in
both processes belonged to genes that were mainly related to devel-
opmental functions. While genes containing hypomethylated CpGs
in cancer were associated with extracellular signaling, those for aging
were, in general, much less enriched in any gene ontology. In the
case of KEGG pathways (Figure 6a; Table S12 and Figure S10),
hypermethylated CpGs in both cancer and aging shared enrichment
for several ontologies, many related to cell metabolic and signaling
pathways. In this respect, hypomethylated CpGs in cancer had some
ontologies in common, while others were specific. Once again, aging
hypomethylated CpGs exhibited much less enrichment in any func-
tion.
To exemplify the similarities and disparities observed for DNA
methylation in aging and cancer, we focused on a number of sig-
nificant dmCpGs from two particular genomic regions, located in
chromosomes 11 and 16 (Figure 6b,c). We observed a substantial
correlation between bivalent posttranslational histone modifica-
tions, especially H3K27me3 and H3K4me1/3, and the presence of
hypermethylated probes in aging and cancer. On the other hand,
DNA hypomethylated regions were more frequently located near
H3K9me3 or H3K4me1 peaks (bottom panel Figure 6b,c) as out-
lined in our previous histone enrichment analyses. A detailed
inspection of the common genes with most abundant dmCpGs in
aging and cancer revealed a similar trend toward DNA hyperme-
thylation at the boundaries of the gene PAX6 (Figure 6b, top
panel). Interestingly, a representative set of cancer cell lines, as
well as fibroblasts derived from patients with Hutchinson-Gilford
progeria, also display higher levels of DNA methylation when
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compared to normal cells in these differentially methylated regions
(Figure 6b, middle panel). On the contrary, the abovementioned
pattern was mainly reversed in the case of the RBFOX1 gene,
located in a region which was preferentially hypomethylated in
cancer (Figure 6c, top and middle panel).
2.7 | Correlations between CpG methylation and
gene expression in aging and cancer
Lastly, we looked at the possible impact in the control of gene
expression of the methylation changes previously found. To address
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this issue, we focused on kidney tissue (KIRC) as this TCGA dataset
displayed a reasonable number of control and cancer patients with
paired methylation and gene expression data. We initially performed
differential gene expression analyses comparing young vs. old or nor-
mal vs. tumoral kidney samples (Figure 7a and Table S13). These
results allowed us to identify a total of 13 and 20,678 differentially
expressed genes (DEGs) in aging and cancer conditions, respectively.
The majority of the aging DEGs were also found in cancer, including,
for example, the CKM gene, which contained a dmCpG in the prox-
imity of its promoter (Figure 7b), was differentially expressed in both
processes (Figure 7c) and displayed a considerable negative correla-
tion between DNA methylation and gene expression in normal kid-
ney (Spearman r = .37, Figure 7d). To further explore the potential
relationships between CpG methylation and gene expression in these
processes, and due to the reduced number of DEGs observed in the
aging context, we decided to perform all potential pairwise correla-
tions between DNA methylation and gene expression using cancer-
or aging-related dmCpGs and genes expressed in a subset of normal
kidney tissue samples (n = 18). This approach enabled us to quantify
the extent to which CpGs whose methylation status changes in can-
cer and aging originally influence gene expression in normal tissue.
We computed a total of 2.58e09 and 3.84e08 correlations
between cancer- and aging-related dmCpGs, respectively, and genes
expressed in the normal KIRC dataset (Figure 7e). Despite the con-
siderable difference in a number of dmCpGs between cancer and
aging, when compared to the total possible number of correlations,
we found similar percentages of strong correlations between DNA
methylation and gene expression in both processes (Table S14).
Moreover, these proportions were also higher than those observed
when sampling random probes from the array and computing their
correlations (see Figure S11). These results indicate that both can-
cer- and aging-related dmCpGs are enriched in CpGs that can influ-
ence, to some extent, gene expression in kidney tissue.
A more detailed inspection of the strongest correlations (>= 0.9
or <= 0.9) identified in these datasets revealed that, in cancer, the
number of unique dmCpG-gene pairs remained similar (~20,000)
regardless of the direction of the observed correlation (Figure 7f,
top). Furthermore, while the number of unique dmCpG-gene pairs in
the aging context was much reduced (~3,000), the proportion com-
pared to the total number of strong correlations observed in a given
dataset remained, to a great extent, similar (Figure 7f, bottom). Inter-
estingly, the differences between the genomic distributions of the
unique hyper- and hypomethylated dmCpG-gene pairs identified in
aging or in cancer followed the same trend to those observed for
the genomic distribution of the hyper- and hypomethylated dmCpGs
identified in each of these processes (Figure 2b,c), with hypermethy-
lated dmCpGs being more enriched in CpG islands in aging as com-
pared to the array (Fisher’s tests; both p < .001, ORs = 2.0, 1.4, for
positively and negatively correlated dmCpGs, respectively), in con-
trast to the enrichment at open sea locations (Fisher’s tests; all
p < .001, ORs = 4.6, 4.1, 2.3 and 2.5 for positively and negatively
correlated dmCpGs in aging and cancer, respectively) and intronic
regions (Fisher’s tests p < .002, <.03, <.001 and <.001, ORs = 2.2,
1.9, 1.6, and 1.7 for positively and negatively correlated dmCpGs in
aging and cancer, respectively) of the hypomethylated dmCpGs in
both processes (Figure 7g,h). It is worth noting that the distribution
of the unique hypermethylated dmCpGs which also control gene
expression was more enriched in open sea locations as compared to
dmCpGs in general in both aging and cancer (Figure 7g as compared
to Figure 2b).
Finally, we compared the unique dmCpGs that displayed strong
correlations between DNA methylation and gene expression in aging
or in cancer (Figure 7i). We observed an extensive overlap between
probes that displayed positive or negative correlations in the two
processes (Fisher’s tests, all p < .001, ORs = 908, 2244, 205, and
171; JIs = 0.57, 0.54, 0.57, and 0.54 for aging and cancer hyper-
and hypomethylated CpGs, respectively). This fact might explain
their similar genomic distributions (Figure 7g,h), indicating that most
of these dmCpGs could play a dual role in the control of their differ-
ent gene expression targets. We also observed a considerable over-
lap between dmCpGs associated with gene expression identified in
aging and cancer processes (Fisher’s tests, both p < .001, ORs = 5.1
and 9.1; JIs = 0.06 and 0.03, for hyper- and hypomethylated CpGs,
respectively). Interestingly, regardless of whether the DNA methyla-
tion change was toward hyper- or hypomethylation, ~ 60–70% of
the aging-related dmCpGs which controlled gene expression were
F IGURE 7 Relationships between DNA methylation and gene expression in aging and cancer. (a) Venn diagrams illustrating the overlap
between DEGs in aging and cancer in the KIRC dataset (see Table S13 for DEG lists). (b) Boxplot depicting the DNA methylation b-values of
the CpG cg19442915 in old and young individuals (n = 5) from the KIRC aging condition. (c) Boxplot showing the gene expression values
(RSEM) of the CKM gene in old and young individuals (n = 5) from the aging condition of the KIRC dataset. (d) Scatterplot showing the
Spearman correlation between DNA methylation (cg19442915) and gene expression (CKM gene) in 18 normal kidney samples. Colored dots
indicate old or young individuals used for the aforementioned aging comparisons. (e) Histograms representing the number of pairwise
correlations that are contained in a given correlation window (from 1 to 1) obtained as the result of computing the correlation between b-
values of dmCpGs identified in cancer or aging and gene expression levels (RSEM) of genes expressed in the KIRC dataset. The number of
dmCpGs used for each of the comparisons is indicated at the bottom. (f) Barplots depicting the number of total (blue) and unique (orange)
dmCpG-gene pairs identified in the previous analysis which displayed correlation scores above 0.9 (pos) or below 0.9 (neg) in cancer (top) or
in aging (bottom) conditions. (g) Stacked barplots indicating relative distribution of unique dmCpGs obtained from the previous correlations
according to their CpG island status. (h) Stacked barplots indicating relative distribution of unique dmCpGs obtained from the previous
correlations according to their gene location status. (i) Venn diagrams illustrating the overlap between dmCpGs identified in aging and in
cancer which displayed strong positive or negative correlations (>0.9 or <0.9) with genes expressed in the normal kidney dataset
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also present in the group of cancer-related dmCpGs (Figure 7i).
These results point toward similarities of cancer- and aging-related
dmCpGs in the control of gene expression in normal tissue, despite
the fact that the number of cancer-related dmCpGs is clearly larger
than their aging counterparts.
3 | DISCUSSION
Although it is widely accepted that cancer is an age-dependent dis-
ease, the underlying molecular mechanisms are still poorly character-
ized. In this work, we have looked at the similarities and differences
in epigenetic changes associated with cancer and aging.
In agreement with previously published data (Fernandez et al.,
2015), we observed that the number of aging- and cancer-associated
DNA methylation changes was variable and, in the case of aging,
had a marked tissue type-dependent component. In general, cancer
displayed strong and bidirectional changes, while, strikingly, hyper-
methylated CpG sites were predominantly observed for the aging
process. These results, which are ostensibly in contrast with the clas-
sically described global hypomethylation changes in cancer and
aging, might potentially arise from the limitations of our study. As
the methylation arrays used in our analyses mainly interrogate
genetic elements and do not include repeated DNA, which covers a
substantial fraction of the genome and frequently loses DNA methy-
lation in tumors and aged cells, the genome-wide landscape may be
different (Ehrlich, 2009). Nonetheless, epigenetic signatures have
been successfully derived previously using array technology (Fernan-
dez et al., 2015; Rakyan et al., 2010; Teschendorff et al., 2010) and
our results are in line with recent studies which report no global
decreases in DNA hypomethylation with aging in diverse mouse tis-
sues, such as liver (Cole et al., 2017; Hahn et al., 2017), hippocam-
pus (Masser et al., 2017), or hematopoietic stem cells (Beerman
et al., 2013; Sun et al., 2014), thus strengthening the validity of our
observations.
The changes in cell type composition that occur with age and
cancer are also well-known confounding factors that could affect
our datasets (Zheng et al., 2017). However, the application of the
SVA method of correction (and Houseman correction for blood) and
the use of a pure-cell dataset such as the glia dataset (Guintivano
et al., 2013) allowed us to tackle this issue in two different ways.
Additionally, the use of the blood validation dataset (Hannum et al.,
2013) allowed us to verify the reliability of our workflow, as in terms
of whole blood dmCpGs we obtained 89% concordance with previ-
ous studies using the same data (Fernandez et al., 2015).
When analyzing the genomic distribution of dmCpGs and, in line
with previously published reports (Cruickshanks et al., 2013; Kulis
et al., 2012; Yuan et al., 2015), we found that hypomethylated CpGs
were enriched at open sea DNA regions, principally intronic and
intergenic, irrespective of the type of process. The distribution of
hypermethylated CpGs was found to be similar to that of the array,
which is to a certain extent to be expected because it was designed
to interrogate a promoter- and CpG dense-biased portion of the
genome. Nonetheless, hypermethylation changes always occurred in
far more CpG-dense regions than hypomethylation changes (Day
et al., 2013; Yuan et al., 2015), and this observed effect was espe-
cially noticeable for aging dmCpGs.
When studying the potential effect of tissue type on DNA
methylation changes, we found, in agreement with recently pub-
lished data (Chen, Breeze, Zhen, Beck & Teschendorff, 2016), that
DNA methylation changes in different tumor types were surprisingly
similar, regardless of the tendency of the alteration. This observation
is conceptually relevant because it has classically been considered
that different tumor types are characterized by specific DNA methy-
lation signatures (Ehrlich & Jiang, 2005; Portela & Esteller, 2010). In
this sense, our data confirm that, although different tumor types
might display specific DNA methylation patterns, there is a signifi-
cant common nexus between them. The analysis of the DNA methy-
lation changes observed with respect to the aging process also
revealed a significant overlap between tissue types, although it is
possible that these results are affected by the variability in the sizes
of the sets of probes detected in the aging analysis.
Our data revealed that dmCpGs shared by two or more tissues
were much less likely to have different behaviors in other tissues,
perhaps pointing toward nonstochastic and possibly functional roles
for these CpGs.
The systematic DNA methylation analyses described in this study
confirm that DNA hypermethylation in aging and cancer is associ-
ated with the same set of histone marks, including the repressive
H3K27me3 and H3K9me3 marks, and the activating H3K4me1/3
posttranslational modifications. Chromatin state analysis revealed
that the hypermethylation-associated H3K27me3 and H3K4me1/3
marks configured bivalent chromatin domains, as has been exten-
sively described in embryonic stem cells (Fernandez et al., 2015;
Ohm et al., 2007; Rakyan et al., 2010; Schlesinger et al., 2007;
Teschendorff et al., 2010; Widschwendter et al., 2007). Moreover,
our data reveal that this chromatin signature is not restricted to only
embryonic stem cells, but rather this trend should be considered an
extended, global tissue-independent chromatin signature of DNA
hypermethylation in aging and cancer. Interestingly, Chen and col-
leagues (Chen et al., 2016) have recently demonstrated that normal
tissue signatures are better predictors of DNA hypermethylation
changes than ESC signatures. Furthermore, hypermethylation
changes were also associated with the repressive histone mark
H3K9me3 (Ohm et al., 2007), which was correlated to ZNF genes
and DNA repeats in our chromatin state analyses, and which might
have a potential relationship with the malignant transformation pro-
cess (Severson, Tokar, Vrba, Waalkes & Futscher, 2013).
Regarding DNA hypomethylation, our results showed that age-
related DNA hypomethylation is associated with the activating his-
tone posttranslational modification H3K4me1, which supports previ-
ously published data (Fernandez et al., 2015). A slight tendency for
the enrichment of H3K27Ac, a histone mark characteristic of active
enhancers (Creyghton et al., 2010), was also detected in our analy-
ses. Intriguingly, the chromatin signature of DNA hypomethylation in
cancer was substantially different, being primarily enriched in the
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posttranslational repressive histone modification H3K9me3, a rela-
tionship that has been investigated in colon and breast cancer (Ber-
man et al., 2011; Hon et al., 2012). This observation might be
conceptually relevant because DNA methylation has been proposed
to be a molecular link between aging and cancer (Fraga, Agrelo &
Esteller, 2007; Klutstein, Nejman, Greenfield & Cedar, 2016). How-
ever, our results suggest that the role of DNA methylation as a pos-
sible link between aging and cancer is more complex than previously
proposed. Importantly, even though many of the observed DNA
methylation changes in aging were not shared by tissues, we were
able to describe a common chromatin signature characteristic of the
aging process.
Regarding the analysis of the chromatin states, DNA
hypomethylation in cancer was associated with heterochromatin
DNA regions, which is in line with previous work (Berman et al.,
2011; Kulis et al., 2012). In contrast, chromatin marks of DNA
hypomethylation in aging were associated with enhancers, rein-
forcing previous observations performed with the Infinium
HumanMethylation27K Beadchip platform (Day et al., 2013). As
DNA methylation changes in enhancers have been shown to play
an important role in gene regulation (Aran, Sabato & Hellman,
2013; Blattler et al., 2014; Heyn et al., 2016), our results suggest
that DNA hypomethylation during aging might have a different
functional role in gene regulation compared to DNA hypomethyla-
tion changes in cancer.
With regard to the potential effectors of the distinct chromatin
signatures, enrichment analyses of transcription factors revealed the
presence of EZH2 and SUZ12 polycomb components at DNA hyper-
methylated sites, both in cancer and aging. Specific aging hyperme-
thylation-associated factors were also observed in our comparisons,
such as REST, which has been reported in previously published data
in blood (Yuan et al., 2015), and has also been correlated with long-
evity (Lu et al., 2014). Concerning DNA hypomethylation, transcrip-
tion factors such as FOS, JUN, and JUND were detected at both
cancer and aging hypomethylated CpG sites, but again aging dis-
played stronger and more varied enrichment, and included the pres-
ence FOSL1/2, other bZIP-domain factors like MAFF and MAFK,
and STAT3, which has been associated with recruitment of the
H3K4 methyltransferase SET9 at promoters (Yang et al., 2010). Alto-
gether, these observations would imply that hypomethylation in
aging displays a more marked functional context than that of cancer,
exhibiting an increased enrichment of some factors also detected at
cancer hypomethylated sites and other specific factors not found
associated with tumoral changes.
Interestingly, our gene ontology analyses revealed similar gene
functionalities affected by cancer and aging DNA hypermethylation,
mainly related to developmental processes, which is in line with the
methylation of bivalent chromatin promoters of developmental regu-
lators in cancer and aging (Easwaran et al., 2012; Rakyan et al.,
2010). On the other hand, DNA hypomethylation in cancer was
mainly associated with functions identified with cellular signaling,
and much lower enrichments in gene functions were found for
hypomethylated CpGs in aging. A preponderance of nongenic
enhancer hypomethylation in aging could potentially explain this
absence of gene function association in our data.
To date, the potential relationships between DNA methylation
and gene expression have only been systematically analyzed in a
small subset of studies (Gevaert, Tibshirani & Plevritis, 2015; Gutier-
rez-Arcelus et al., 2013, 2015), and the potential effects of these
relationships on aging and cancer are yet to be elucidated. To this
end, we explored the establishment of potential correlations
between these two processes using the TCGA-KIRC dataset. While
most correlative studies focus on CpGs located at particular genomic
regions, such as DNA promoters (Moarii, Boeva, Vert & Reyal, 2015)
and cis-related correlations with the gene of interest (Gutierrez-
Arcelus et al., 2015), we performed a nonbiased approach focusing
on all the potential pairwise comparisons that could be identified
between any significant dmCpG and the genes expressed in the con-
text of normal kidney tissue. The limitations of these analyses did
not allow us to distinguish between direct (i.e., mediated by the
effects of the DNA methylation process itself) or indirect regulation
of gene expression governed by the subsequent expression of other
regulatory factors. Nonetheless, we observed that both aging and
cancer dmCpGs influence gene expression to a similar extent, as
these processes show the same proportions of strong correlations
between DNA methylation and gene expression in normal kidney tis-
sue. Moreover, we observed a similar number of positive and nega-
tive correlations between DNA methylation and gene expression, as
described in Gutierrez-Arcelus et al., 2013, with most of these posi-
tively and negatively correlated dmCpGs overlapping substantially,
suggesting that these CpG sites may play a dual role in the control
of gene expression, or the involvement of other factors.
Finally, we found that most of the tumor types analyzed in this
study did not show age-associated DNA methylation changes, which
is in agreement with the reprogramming of the epigenetic clock in
cancer cells (Horvath, 2013). As an exception, we identified age-
associated dmCpGs in thyroid tumors. Uncommonly, thyroid cancer
includes age as a prognostic indicator in most staging systems (Hay-
mart, 2009), implying that these cancers do suffer age-related
changes in their behavior. Intriguingly, this tissue displayed the low-
est level of DNA methylation changes in cancer and one of the low-
est in aging. Although the reasons for the different behavior of DNA
methylation changes in thyroid are currently unknown, they could be
related to the good prognosis that typically characterizes this type of
tumor. In fact, Yang Z. and collaborator’s “epiTOC” mitotic clock
(Yang et al., 2016) shows thyroid cancer to have the least deviation
from the behavior of its normal tissue. In this regard, future research
should be conducted to address this issue.
In conclusion, our results indicate that hyper- and hypomethy-
lated changes in aging and cancer each have similar genomic distri-
butions and manifest tissue-independent trends in both processes.
We confirm that chromatin signatures of DNA hypermethylation in
aging and cancer are similar but, strikingly, we demonstrate that they
are different for DNA hypomethylation. Collectively, our data sug-
gest that the possible role of DNA methylation as a molecular link
between aging and cancer is more complex than previously thought.
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4 | EXPERIMENTAL PROCEDURES
4.1 | Data acquisition
HumanMethylation450 BeadChip (Illumina, California, USA) DNA
methylation data (Level 3) corresponding to normal or primary tumors
from breast (BRCA), kidney (KIRC), thyroid (THCA), skin (SKCM), and
glia (GBM) samples were obtained from TCGA consortium via UCSC
Xena Public Data Hub (http://xena.ucsc.edu/). Kidney, skin, and glia
tissue datasets were enlarged for control cases using additional sam-
ples from KIRP (TCGA), skin (Bormann et al., 2016), and glia (Guinti-
vano et al., 2013), respectively. Tissues were chosen based on disease
prevalence, control data availability, and previous literature analyses to
include both novel and pre-analyzed tissues. We also performed analy-
ses on two supplementary datasets: lung adenocarcinoma (LUAD) and
control TCGA data, and whole blood from a healthy cohort (Hannum
et al., 2013). Extended information about the samples for each tissue
type is shown in Tables 1, S1 and S9. Data were preprocessed as
detailed in supporting information.
4.2 | Differential DNA methylation analyses
Differentially methylated probes (dmCpGs) in aging and cancer were
calculated with the R package limma (version 3.32.2) (Ritchie et al.,
2015). Briefly, a linear model between methylation levels as response
variable, the variable of interest (either age group or sample_type), and
surrogate variables (see Supplementary Methods) was fitted for each
of the analyses, adjusting p-values to control for false discovery rate
(FDR < 0.05). For the calculation of age-related dmCpGs, samples
were divided into age quantiles in such a way as to obtain groups with
sizes of n = 15–30, and comparisons were performed between the
upper (OLD) and the lower (YOUNG) quantile. Cancer-related dmCpGs
were calculated between normal tissue (Solid Tissue Normal) and tumor
samples (Primary Tumor) as indicated in Tables 1, S1 and S2. Probes
with M-value changes of <0.5 were not considered as dmCpGs, as has
been suggested elsewhere (Du et al., 2010). Venn diagrams of rela-
tionships between dmCpGs were generated with the online resource
provided by the UGent/VIB bioinformatics unit (http://bioinformatics.
psb.ugent.be/webtools/Venn/). Further enrichment analyses were
performed by means of two-sided Fisher’s tests (p < .05 significance
threshold), measuring effect size either by odds ratios (OR), or by the
difference between observed counts and expected hypergeometric
mean (EHM), employing appropriate backgrounds of interrogated
probes for the given context.
Density of CpG (related to Figure 2a), CGI status and genomic
region (related to Figure 2b,c), and analysis, DNA methylation age
(related to Figure 1d), and gene and KEGG ontology (related to
Figure 6a) analyses are further detailed in Supplementary Methods.
4.3 | Region set enrichment analysis
Enrichment analyses were performed with the R package LOLA (ver-
sion 1.4.0) (Sheffield & Bock, 2016), which looks for over-enrichment
by conducting one-sided Fisher’s tests (p < .05 significance thresh-
old), by comparing overlap of probes (10 bp probe-centered win-
dows) with the dataset of interest. Enrichment of histone marks was
determined using histone ChIP-seq peak tracks (H3K4me1,
H3K4me3, H3K27me3, H3K36me3, H3K9me3, and H3K27ac marks)
from 98 epigenomes (primary tissues, cultures, and cell lines)
obtained from the NIH Roadmap and ENCODE projects (Bernstein
et al., 2010; Consortium 2012) (datasets obtained from http://datab
io.org/regiondb) (see Table S8). The same method was employed for
chromatin-segment analysis using NIH Roadmap’s ChromHMM
expanded 18-state model tracks for the same 98 epigenomes (see
Figure S7 and Table S10, custom database generated with data
obtained from http://egg2.wustl.edu/roadmap/). In a similar fashion,
ChIP-seq peak tracks from ENCODE for transcription factor binding
sites (TFBS) comprising 689 datasets corresponding to 188 TFs ana-
lyzed in 91 cell and tissue types were employed for TFBS enrich-
ment analysis (http://databio.org/regiondb, see Table S11).
4.4 | Gene expression analyses
Gene expression data corresponding to RNAseq HTSeq-Counts
from the GDC TCGA Kidney Clear Cell Carcinoma (KIRC) cohort
were obtained from UCSC Xena Public Data Hub (http://xena.uc
sc.edu/, dataset ID: TCGA-KIRC/Xena_Matrices/TCGA-KIRC.htseq_-
counts.tsv). Samples were filtered to fulfill the criteria of using
only those cases with paired DNA methylation and gene expres-
sion data. Log2(count+1) data were further transformed to obtain
integer count reads per gene condition. Nonvariable and low-
expressed genes (sum of expression across all the samples <1,000
counts) were removed to reduce the number of noninformative
conditions. Differential expression analyses were performed with
the R package DESeq2 (version 1.16.1) (Love, Huber & Anders,
2014), using the standard workflow and parameters, defining dif-
ferentially expressed genes if they satisfied p < .05 after adjust-
ment for multiple testing. For gene expression and DNA
methylation correlation analyses, RNAseqV2 log2(RSEM+1) normal-
ized level 3 TCGA gene expression data were obtained for kidney
normal tissue (KIRC) via UCSC Xena Public Data Hub (http://xena.
ucsc.edu/). Samples were filtered so as to use only those with
paired DNA methylation data. Nonvariable and low-expression
genes (those with the sum of expression between all the samples
of <10) were discarded. After filtering, pairwise Spearman correla-
tions between DNA methylation level and gene expression level
were calculated for all the combinations of probes and genes in
normal kidney tissue samples, using probes that were previously
detected dmCpGs in cancer and aging.
4.5 | Availability
All data generated during this study are included in this published
article and its supplementary information files and are also available
in the Zenodo public repository, https://doi.org/10.5281/zenodo.
1086491.
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